Engraftment and Measurable Residual Disease Monitoring after Hematopoietic Stem Cell Transplantation : Comparison of Two Chimerism Test Strategies, Next-Generation Sequencing versus a Combination of Short-Tandem Repeats and Quantitative PCR
Copyright © 2024 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved..
Chimerism testing supports the study of engraftment and measurable residual disease (MRD) in patients after allogeneic hematopoietic stem cell transplant. In chimerism MRD, relapse can be predicted by increasing mixed chimerism (IMC), recipient increase ≥0.1% in peripheral blood, and proliferating recipient cells as a surrogate of tumor activity. Conventionally, the combination of short-tandem repeat (STR) and quantitative PCR (qPCR) was needed to ensure assay sensitivity and accuracy in all chimerism status. We evaluated the use of next-generation sequencing (NGS) as an alternate technique. The median numbers of informative markers in unrelated/related cases were 124/82 (NGS; from 202 single-nucleotide polymorphism), 5/3 (qPCR), and 17/10 (STR). Assay sensitivity was 0.22% (NGS), 0.1% (qPCR), and 1% (STR). NGS batch (4 to 48 samples) required 19.60 to 24.80 hours and 1.52 to 2.42 hours of hands-on time (comparable to STR/qPCR). NGS assay cost/sample was $91 to $151, similar to qPCR ($99) but higher than STR ($27). Using 56 serial DNAs from six post-transplant patients monitored by the qPCR/STR, the correlation with NGS was strong for percentage recipient (y = 1.102x + 0.010; R2 = 0.968) and percentage recipient change (y = 0.892x + 0.041; R2 = 0.945). NGS identified all 17 IMC events detected by qPCR (100% sensitivity). The NGS chimerism provides sufficient sensitivity, accuracy, and economical/logistical feasibility in supporting engraftment and MRD monitoring.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
The Journal of molecular diagnostics : JMD - 26(2024), 4 vom: 01. März, Seite 233-244 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Aiwen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 22.03.2024 Date Revised 22.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jmoldx.2024.01.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367966301 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367966301 | ||
| 003 | DE-627 | ||
| 005 | 20240323000702.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240203s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jmoldx.2024.01.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1341.xml |
| 035 | |a (DE-627)NLM367966301 | ||
| 035 | |a (NLM)38307253 | ||
| 035 | |a (PII)S1525-1578(24)00013-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Aiwen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Engraftment and Measurable Residual Disease Monitoring after Hematopoietic Stem Cell Transplantation |b Comparison of Two Chimerism Test Strategies, Next-Generation Sequencing versus a Combination of Short-Tandem Repeats and Quantitative PCR |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2024 | ||
| 500 | |a Date Revised 22.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Chimerism testing supports the study of engraftment and measurable residual disease (MRD) in patients after allogeneic hematopoietic stem cell transplant. In chimerism MRD, relapse can be predicted by increasing mixed chimerism (IMC), recipient increase ≥0.1% in peripheral blood, and proliferating recipient cells as a surrogate of tumor activity. Conventionally, the combination of short-tandem repeat (STR) and quantitative PCR (qPCR) was needed to ensure assay sensitivity and accuracy in all chimerism status. We evaluated the use of next-generation sequencing (NGS) as an alternate technique. The median numbers of informative markers in unrelated/related cases were 124/82 (NGS; from 202 single-nucleotide polymorphism), 5/3 (qPCR), and 17/10 (STR). Assay sensitivity was 0.22% (NGS), 0.1% (qPCR), and 1% (STR). NGS batch (4 to 48 samples) required 19.60 to 24.80 hours and 1.52 to 2.42 hours of hands-on time (comparable to STR/qPCR). NGS assay cost/sample was $91 to $151, similar to qPCR ($99) but higher than STR ($27). Using 56 serial DNAs from six post-transplant patients monitored by the qPCR/STR, the correlation with NGS was strong for percentage recipient (y = 1.102x + 0.010; R2 = 0.968) and percentage recipient change (y = 0.892x + 0.041; R2 = 0.945). NGS identified all 17 IMC events detected by qPCR (100% sensitivity). The NGS chimerism provides sufficient sensitivity, accuracy, and economical/logistical feasibility in supporting engraftment and MRD monitoring | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Macecevic, Stacey |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Dawn |e verfasserin |4 aut | |
| 700 | 1 | |a Allen, Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Mandley, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Kawczak, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Jurcago, Raymond |e verfasserin |4 aut | |
| 700 | 1 | |a Tyler, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Casey, Heather |e verfasserin |4 aut | |
| 700 | 1 | |a Bosler, David |e verfasserin |4 aut | |
| 700 | 1 | |a Sobecks, Ronald |e verfasserin |4 aut | |
| 700 | 1 | |a Hamilton, Betty |e verfasserin |4 aut | |
| 700 | 1 | |a Sauter, Craig |e verfasserin |4 aut | |
| 700 | 1 | |a Mineishi, Shin |e verfasserin |4 aut | |
| 700 | 1 | |a Claxton, David |e verfasserin |4 aut | |
| 700 | 1 | |a Shike, Hiroko |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of molecular diagnostics : JMD |d 1999 |g 26(2024), 4 vom: 01. März, Seite 233-244 |w (DE-627)NLM111386683 |x 1943-7811 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2024 |g number:4 |g day:01 |g month:03 |g pages:233-244 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jmoldx.2024.01.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2024 |e 4 |b 01 |c 03 |h 233-244 | ||